glp 1 drugs history Market Overview: GLP-1 Agonists and the Obesity Market | Blog History of GLP-1: From Discovery

Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs

The exciting beyond obesity frontier for GLP-1 drugs is their potential to treat conditions where inflammation, or other non-obesity factors, are the primary cause

GLP-1 weight loss injections are considered safe for most individuals when used under the supervision of a healthcare provider

The WHO guideline specifically recommends GLP-1 therapies for adults with obesity, defined as BMI 30 or higher

2 Data from a cohort of patients with a high risk for cardiovascular events (the CORE-Thailand Registry) show that 83.8% of patients who had established atherosclerotic CVD (ASCVD) and multiple CV risk factors have either diabetes or impaired fasting glucose

Seven of these trials are expected to report results in 2026